Fosun Adgenvax

Adgenvax is a clinical-stage biotechnology company specializing in the development of innovative vaccines and oncolytic virus therapies using advanced adenoviral vector platforms. Headquartered in Suzhou, China, the company was established with significant backing from Fosun Pharma to address unmet medical needs in infectious diseases and oncology. Its lead programs include therapeutic vaccines for Human Papillomavirus (HPV) and Hepatitis B (HBV), as well as next-generation oncolytic viruses for solid tumors. Adgenvax leverages its proprietary vector technology to enhance immune responses and improve the safety profile of its candidates. The company plays a strategic role within the Fosun Pharma ecosystem, focusing on high-growth vaccine markets and immunotherapy.